H.C. Wainwright reiterates a Buy rating on Solid Biosciences (SLDB) after Sarepta (SRPT) disclosed a second patient death due to acute liver failure following treatment with Elevidys. The news underscores the favorable safety profile of Solid’s SGT-003, the analyst tells investors in a research note. The firm believes SGT-003 has the most favorable safety profile among the leading Duchenne muscular dystrophy gene therapies either in clinic or in the market. Wainwright expects a meaningful share of ambulatory patients to transition from Elevidys to SGT-003.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences Approves Equity Plan Amendment at Meeting
- Solid Biosciences reports inducement grants under Nasdaq listing rule
- Solid Biosciences Reports Increased Loss Amid R&D Expansion
- Solid Biosciences: Undervalued Gem with Promising Gene Therapy Pipeline and Upcoming Catalysts
- Solid Biosciences’ SGT-003 Therapy Shows Promise in DMD Treatment, Earning Buy Rating from Analyst